新闻资讯
News Inforamtion
Recently, Nuoyuan Medical’s core product—the 4K endoscopic fluorescence imaging system—successfully obtained certification under the European Union’s new Medical Device Regulation (MDR). This milestone signifies that Nuoyuan Medical has earned international recognition for its product quality and technological strength, injecting strong momentum into the company’s global expansion!
Here is placeholder text.
Paitai Jinglv, a Class 1 new drug independently developed by Nuoyuan Medical, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on December 20, 2024! This milestone achievement is yet another testament to the company’s core R&D team’s profound expertise and relentless efforts in the biopharmaceutical field. It also marks the first IND approval for a folate-receptor-targeted contrast agent in China, following the successful FDA approval and market launch of Cytalux (OTL-38), the world’s first folate-receptor-targeted imaging agent. This breakthrough underscores China’s significant progress in this field. Paitai Jinglv has already been granted invention patents in China, the United States, Europe, and Japan, highlighting its global innovative strength.
Here is placeholder text.
From August 28 to 30, 2024, the 18th Sullivan China Growth, Innovation & Leadership Summit and the 3rd New Investment Conference were held in Shanghai. This year’s conference is themed “Unite New Forces, Achieve Quality-Driven Future,” aiming to bring together the wisdom and strength of global industry leaders, academics, research institutions, investors, and media to jointly explore new growth drivers, new markets, and new development paths for China’s economy in the new era.
Here is placeholder text.
On the afternoon of December 14, Jin Nengming, Secretary of the Party Committee of China Pharmaceutical University, visited Nanjing Nuoyuan Medical Device Co., Ltd., a company founded by Cai Huiming, Chairman and alumnus of the Class of 1981. Accompanying him on the visit and exchange were several prominent alumni from the Class of 1981, including Tao Desheng, Vice Chairman of Lizhu Pharmaceutical Group; Sun Feng, Chairman of Shanghai Kangcheng Investment Management Co., Ltd.; and Zhang Yu, Chairman of Nanjing Yikang Pharmaceutical Co., Ltd., also an alumnus of the Class of 1981 based in Nanjing.
Here is placeholder text.
Internationally, medical endoscopes have undergone more than 200 years of development, going through three major stages: the initial stage, during which physicians began observing patients’ internal tissues and organs; the development stage, marked by the need to meet ever-changing clinical demands; and the optimization stage, aimed at satisfying increasingly diverse and growing clinical needs. However, domestically produced medical endoscopes started relatively late, with a development history of just over 30 years. Yet, alongside the rise of China as a global power, these endoscopes have made remarkable progress. Many Chinese companies have achieved breakthroughs in both quality and quantity in certain specialized segments of the medical endoscope market.
Here is placeholder text.
[Good News] Nuoyuan Medical Wins First Prize from the China Invention Association
Recently, the China Invention Association [National Science and Technology Award Certificate No. 0123] awarded the highest prize—the First Prize—of the China Invention Association’s “Invention and Entrepreneurship Award for Innovation” to two organizations and their respective leaders: Professor Zhang Chenping, head of the Ninth People’s Hospital of Shanghai Jiao Tong University, and Chairman Cai Huiming, head of Nanjing Nuoyuan Medical Device Co., Ltd. This award recognizes their outstanding achievements in “the integration and innovation of diagnostic and therapeutic approaches for head and neck malignant tumors.”
Here is placeholder text.
Noyuan Medical has successfully been selected as a (first-batch) innovative product of Nanjing City.
Recently, the Nanjing Municipal Bureau of Industry and Information Technology published the list of products selected for the first batch of Nanjing Innovative Products in 2022. Nuoyuan Medical’s “Endoscopic Fluorescence Imaging System,” thanks to its ultra-high-sensitivity innovative technology, was successfully included on the list.
Here is placeholder text.
Noyuan Medical’s development has entered the fast lane. The company’s overall strategic layout and product pipeline are advancing rapidly in line with its established development strategy. Guided by national and provincial key research projects, the company is deeply committed to the field of intraoperative fluorescence imaging technology, and the vision of becoming a leader in precision medical technologies has consistently permeated every stage of its development.
Here is placeholder text.
Contact Us
Headquarters: Building Shengmingyuan, No. 18 Ziyun Avenue, Qinhuai District, Nanjing City
Factory: No. 18, Fuzhian South Road, Nanjing Fourth Bridge Economic Park, Liuhe District, Nanjing City
Email:yangliu@nuoyuanmedical.cn
Copyright © 2025 Nanjing Nuoyuan Medical Device Co., Ltd. All Rights Reserved.